Towards Improved Human In Vitro Models for Cardiac Arrhythmia: Disease Mechanisms, Treatment, and Models of Atrial...

Area of Science:

• Cardiology
• Biomedical Engineering
• Pharmacology

Background:

• Heart rhythm disorders, particularly atrial fibrillation (AFib), impose a substantial economic burden and diminish patient quality of life.
• Arrhythmias stem from genetic factors or cardiac tissue remodeling due to aging and heart disease.
• Current treatments manage AFib symptoms but do not address underlying causes.

Purpose of the Study:

• To review the key features, epidemiology, risk factors, and causes of atrial fibrillation.
• To discuss existing and emerging therapeutic strategies for AFib.
• To evaluate current models for studying cardiac arrhythmias and identify opportunities for innovation in drug screening platforms.

Main Methods:

• Review of scientific literature on atrial fibrillation, its mechanisms, and therapeutic approaches.
• Analysis of current arrhythmia models, including animal models, in silico simulations, and in vitro systems.
• Focus on human pluripotent stem cell (hPSC)-derived cardiomyocytes as a model system.

Main Results:

• Atrial fibrillation is the most prevalent cardiac arrhythmia with complex underlying mechanisms.
• Existing models have limitations in fully recapitulating AFib pathophysiology and facilitating drug discovery.
• hPSC-derived cardiomyocytes offer a promising platform for disease modeling and drug screening.

Conclusions:

• Innovative test models are essential for advancing the understanding of AFib's root causes.
• Developing advanced platforms, such as those using hPSC-derived cardiomyocytes, is critical for effective AFib drug development.
• Addressing the fundamental mechanisms of AFib requires novel research models beyond current therapeutic limitations.